Showing 2601-2610 of 3597 results for "".
- Valeant Issues Updated Financial Guidancehttps://practicaldermatology.com/news/valeant-issues-updated-financial-guidance/2458779/Valeant Pharmaceuticals International, Inc. announced updated financial guidance for the fourth quarter and full year 2015 as well as new guidance for full year 2016. "We are very excited about the strong future given our broad portfolio of brands, our upcoming launch products and ou
- Galderma and ZELTIQ Announce US Collaboration in Aestheticshttps://practicaldermatology.com/news/galderma-and-zeltiq-announce-us-collaboration-in-aesthetics/2458785/Galderma and ZELTIQ Aesthetics, Inc. entered into a new collaboration across the companies’ innovative aesthetic brands and offerings. Effective immediately, the creation of this nationwide collaboration will provide healthcare professionals and consumers with greater access to a robust ran
- Revision Skincare Announces Partnership with World Champion Gymnast Aly Raismanhttps://practicaldermatology.com/news/revision-skincare-announces-partnership-with-world-champion-gymnast-aly-raisman/2458824/World Champion gymnast and three-time Olympic gold medalist Aly Raisman is now an ambassador for the Revision Skincare brand. “My partnership with Revision Skincare is very important to me because I used to struggle with skin problems before using their products,” Ms. Raisman
- Syneron Candela Announces New FDA Clearance for the CO2RE Systemhttps://practicaldermatology.com/news/syneron-candela-announces-new-fda-clearance-for-the-co2re-system/2458825/The FDA has granted numerous additional indications for use of Syneron Medical Ltd.’s CO2RE CO2 device. This clearance, including more than 90 specific indications in total, significantly expands the business opportunity for CO2RE users for high patient dema
- One Quarter of Americans Misled by Online Info: Surveyhttps://practicaldermatology.com/news/one-quarter-of-americans-misled-by-online-info-survey/2458841/One in four Americans (24 percent) say they have been misled by information about an illness or medical symptom from an unverified online source, according to a new survey from Merck Manuals. That figure increases to 30 percent among parents with children under 18 and jumps to 43 percent among mi
- Celgene Announces Results From Ongoing Phase 3 LIBERATE Trial of Otezla for Psoriasishttps://practicaldermatology.com/news/celgene-announces-results-from-ongoing-phase-3-liberate-trial-of-otezla-for-psoriasis/2458838/Results from Celgene Corporation’s ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis presented at 24th European Academy of Dermatology and Venereology show that half of psoriasis patients treated with oral Otezla achieved PASI
- LEO Pharma Inc. Announces FDA Approval of Enstilar Foam for Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-inc-announces-fda-approval-of-enstilar-foam-for-plaque-psoriasis/2458842/The FDA approved LEO Pharma Inc’s Enstilar for the topical treatment of plaque psoriasis in adults 18 years of age and older. Enstilar is a once-daily, alcohol free foam formulation in a pressurized spray can that allows application across large body areas of plaque psoriasis. In th
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drughttps://practicaldermatology.com/news/kythera-biopharmaceuticals-announces-fda-approval-of-kybellatm-also-known-as-atx-101-first-and-only-submental-contouring-injectable-drug/2458953/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:
- Nerium International Announces Exclusive Usage of Anti-Aging Ingredient SIG-1273https://practicaldermatology.com/news/nerium-international-announces-exclusive-usage-of-anti-aging-ingredient-sig-1273/2458970/Nerium International added new ingredient, SIG-1273®, to the Optimera Formula of its Age-Defying Night and Day Creams. Engineered by Princeton University biochemist, Jeffry Stock, SIG-1273 is the result of 20 years of intensive biomedical skincare research, accordi